LaytonMPariseMECampbellCC. Mosquito-transmitted malaria in New York City 1993. Lancet1995; 346:729–31.
2.
The Progress of the Nations - UNICEF, 1997;31.
3.
BjorkmanAPhillips-HowardP. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg1990; 84:177–80.
4.
RieckmanKHDavisDRHuttonDC. Plasmodium vivax resistance to chloroquine. Lancet1989; ii:1183.
5.
MurphyGSBasriHPurnomo. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet1993; 341:96–100.
6.
LuzziGAWarrellDABarnesAJDunbarEM. Treatment of primaquine resistant Plasmodium vivax malaria. Lancet1992; 340:310.
7.
DohertyJFDayJHWarhurstDCChiodiniPL. Treatment of Plasmodium vivax malaria - time for a change. Trans R Soc Trop Med Hyg1997; 91:76.
8.
AlonsoPLLindsaySWArmstrongJRM. The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet1991; 337:1499–502.
9.
D'AlessandroUOlaleyeBOMcGuireW. Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bed net programme. Lancet1995; 345:479–83.
10.
NevillCGSomeESMung'alaVO. Insecticide treated bed nets reduce mortality and severe morbidity from malaria among children on the Kenyan coastTrop Med Int Hlth1996; 1:139–46.
11.
D'AlessandroUOlaleyeBLangerockP. The Gambian National Impregnated Bed Net Programme: evaluation of effectiveness by means of case control studies. Trans R Soc Trop Med Hyg1997; 91:638–42.
12.
MarshK. Immunology of human malaria. In: GillesHMWarrellDA (eds). Essential malariology. London: Edward Arnold, 1993.
13.
MolineauxL. Nature's experiment: what implications for malaria prevention. Lancet1997; 349:1637.
14.
SnowRWOmumboJALoweB. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet1997; 349:1650–4.
15.
Editorial. Towards a malarial vaccine. Lancet1992; 339:586–7.
TargettGAT. Malaria - advances in vaccines. Curr Op Inf Dis1995; 8:322–7.
18.
BrownAESingharajPWebsterHK. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine1994; 12:102–8.
19.
StouteJASlaouiMHeppnerDG. A preliminary evacuation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med1997; 336(2):86–91.
20.
TsujiMZavalaF. ‘Recombinant viral vaccines against malaria’ at XIVth International Congress for Tropical Medicine and Malaria, Nov. 1996, Nagasaki, Japan.
21.
YangSCarrollMWTorres-DuarteAP. Addition of the MSAI signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus. Vaccine1997; 15(12–13):1303–13.
22.
ValeroMVAmadorLRGalindoC. Vaccination with SPf66, a chemically synthesised vaccine against Plasmodium falciparum malaria in ColombiaLancet1993; 341:705–10.
23.
AlonsoPLSmithTSchellenbergJRMA. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern TanzaniaLancet1994; 344:1175–81.
24.
D'AlessandroULeachADrakeleyCJ. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet1995; 346:462–67.
25.
NostenFLuxembergerCKyleDE. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Lancet1996; 348:701–7.
26.
GentonBAl-YamanFReberR. ‘Safety and immunogenicity of a three-component blood stage vaccine (p190, MSA-2, RESA) against Plasmodium falciparum malaria in adults living in a highly endemic area of Papua New Guinea’ at XIVth International Congress for Tropical Medicine and Malaria, Nov. 1996, Nagasaki, Japan.
27.
RickmanLSLongGWOberstR. Rapid diagnosis of malaria by acridine orange staining of centrifuged parasites. Lancet1989; i:68–71.
SpielmanAPerroneJBTeklehaimanotA. Malaria diagnosis by direct observation of centrifuged samples of blood. Am J Trop Med Hyg1988; 39:337–42.
30.
ShiffCJPremjiZMinjasJN. The rapid manual ParaSight-FÔ test. A new diagnostic tool for Plasmodium falciparum infection. Trans R Soc Trop Med Hyg1993; 87:646–8.
31.
GarciaMKirimoamaSMarlboroughD. Immunochromatographic test for malaria diagnosis. Lancet1996; 347:1549.
32.
DurrheimDNla GrangeJJPGovereJMngomezuluNM. Accuracy of a rapid immunochromatographic card test for Plasmodium falciparum in a malaria control programme in South Africa. Trans R Soc Trop Med Hyg1998; 92:32–3.
33.
BanchongaksornTYomokgulPPanyimS. A field trial of the ParaSight-FÔ test for the diagnosis of Plasmodium falciparum infection. Trans R Soc Trop Med Hyg1996; 90:244–5.
34.
KodisingheHMPereraKLRLPremawansaS. The ParaSight-FÔ dipstick test as a routine diagnostic tool for malaria in Sri Lanka. Trans R Soc Trop Med Hyg1997; 91:398–402.
35.
Di PerriGOlliaroPNardiS. The ParaSight-FÔ rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg1997; 91:403–5.
36.
BartoliniAStrohmeyerMSabatinelliG. False positive ParaSight-FÔ test for malaria in patients with rheumatoid factor. Trans R Soc Trop Med Hyg1998; 92:33–4.
37.
SinghNValechaNSharmaVP. Malaria diagnosis by field workers using an immunochromatographic test. Trans R Soc Trop Med Hyg1997; 91:396–7.
38.
CraigMHSharpBL. Comparative evaluation of four techniques for the diagnosis of Plasmodium falciparum infections. Trans R Soc Trop Med Hyg1997; 91:279–82.
39.
SchlagenhaufP. Mefloquine, methodologies, and the media. J Trav Med1996; 3:197–9.
40.
LobelHOMianiMEngT. Long term malaria prophylaxis with weekly mefloquine. Lancet1993; 341:848–51.
41.
SteffenRFuchsESchildknechtJ. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet1993; 341:1299–303.
42.
CroftAMJClaytonTCWorldMJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg1997, 91:199–203.
43.
CroftAMJWorldMJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet, 1996; 347:326.
44.
PhilipsMAKassRB. User acceptability patterns for mefloquine and doxycycline malaria prophylaxisJ Trav Med1996; 3:40–5.
45.
BarrettPJEmminsPDClarkePDBradleyDJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as anti-malarial prophylaxis: postal and telephone survey of travellers. BMJ1996; 313:525–8.
46.
MittelholzerMLWallMSteffenRSturchlerD. Malaria prophylaxis in different age groups. J Trav Med1996; 4:219–23.
47.
CroftAGarnerP. Mefloquine to prevent malaria: a systematic review of trials. BMJ1997; 315:1412–16.
48.
MacPhersonDGambleKTessierD. ‘Mefloquine tolerance - randomized double blinded placebo controlled study using a loading dose of mefloquine in pre-exposed travellers’ at Vth International Conference on Travel Medicine, March 1997, Geneva, Switzerland.
49.
FryauffDJBairdJKBasriH. Randomised placebo controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet1995; 346:1190–3.
50.
BairdKFryauffDWeissWHoffmanS. ‘Trials of primaquine for prophylaxis against malaria in Indonesia and Kenya’ at XIVth International Congress for Tropical Medicine and Malaria, Nov 1996, Nagasaki, Japan.
51.
ShanksGD. ‘New issues in the chemoprophylaxis of malaria in travellers’ at Vth International Conference on Travel Medicine, March 1997, Geneva, Switzerland.
52.
WilairatPPetmitrPPongvilairatG. ‘Gametocidal effect of Pyronaridine and 9-analinoacridines on Plasmodium falciparum’ at XIVth International Congress for Tropical Medicine and Malaria, Nov. 1996, Nagasaki, Japan.
53.
RingwaldPBickiiJBascoL. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria. Lancet1996; 347:24–8.
54.
WinstanleyP. Pyronaridine: a promising drug for Africa?Lancet1997; 347:2–3.
55.
Editorial. Rediscovering wormwood: qinghaosu for malaria. Lancet1992; 339:649–51.
56.
PriceRNNostenFLuxembergerC. Effects of artemisinin derivatives on malaria transmissibility. Lancet1996; 347:1654–8.
57.
Van HensbreoekMBOnyiorahEJaffarS. A trial of artemether or quinine in children with cerebral malaria. N Eng J Med1996; 335:69–75.
58.
LooareesuwanSViravanCVanijanontaS. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet1992; 339:821–4.
59.
WardS. ‘An overview of pre-clinical evaluation of CGP 56697 at Satellite Symposium ‘A New Anti malarial Combination CGP 56697’ at Vth International Conference on Travel Medicine, March 1997, Geneva, Switzerland.
60.
GreenwoodB. ‘Review of clinical trials of CGP 56697 anti-malarial’ at Satellite Symposium ‘A New Antimalarial Combination CGP 56697’ at Vth International Conference on Travel Medicine, March 1997, Geneva, Switzerland.
61.
RoyceC. ‘Update on clinical trials in progress’ at Satellite Symposium ‘A New Antimalarial Combination CGP 56697’ at Vth International Conference on Travel Medicine, March 1997, Geneva, Switzerland.
62.
GutteridgeWE. ‘Modes of action of atovaquone and proguanil and biochemical basis for their interaction’ at Satellite Symposium ‘The role of Malarone in anti-malarial chemotherapy’ at XIVth International Congress for Tropical Medicine and Malaria, November 1996, Nagasaki, Japan.
63.
LooareesuwanSKyleDEWailairatanaP. ‘Comparative clinical trial of a combination of atovaquone and proguanil with mefloquine in the treatment of acute P. falciparum malaria in adults in Thailand’ at Satellite Symposium ‘The role of Malarone in anti-malarial chemotherapy’ at XIVth International Congress for Tropical Medicine and Malaria, November 1996, Nagasaki, Japan.
64.
de AlencarFECeruttiCJrDurlacherRR. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis1997; 175(6):1544–7.
65.
RadloffPDPhillipsJNkeyiM. Atovaquone and proguanil for Plasmodium falciparum malariaLancet1996; 347:1511–4.
66.
AnabwaniGEsamaiF. ‘Comparative trial of a combination of atovaquone plus proguanil versus halofantrine in the treatment of malaria in children in Kenya’ at Satellite Symposium ‘The role of Malarone in anti-malarial chemotherapy’ at XIVth International Congress for Tropical Medicine and Malaria, November 1996, Nagasaki, Japan.
67.
ShanksGDAndersenSOlooA. ‘The first field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) as a suppressive prophylactic agent against Plasmodium falciparum malaria’ at Satellite Symposium ‘The role of Malarone in anti-malarial chemotherapy’ at XIVth International Congress for Tropical Medicine and Malaria, November 1996, Nagasaki, Japan.
